Review
Copyright ©2007 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jun 7, 2007; 13(21): 2901-2912
Published online Jun 7, 2007. doi: 10.3748/wjg.v13.i21.2901
Diet, H pylori infection and gastric cancer: Evidence and controversies
Alba Rocco, Gerardo Nardone
Alba Rocco, Gerardo Nardone, Department of Clinical and Experimental Medicine, Gastroenterology Unit, University “Federico II”, Naples, Italy
Author contributions: All authors contributed equally to the work.
Correspondence to: Gerardo Nardone, MD, Dipartimento di Medicina Clinica e Sperimentale, Unità di Gastroenterologia, Università degli Studi di Napoli “Federico II”, Via Pansini n° 5, Napoli 80131, Italy. nardone@unina.it
Telephone: +39-81-7464293 Fax: +39-81-7464293
Received: December 1, 2006
Revised: December 15, 2006
Accepted: December 20, 2006
Published online: June 7, 2007

Abstract

Despite decreasing incidence and mortality rates, gastric cancer (GC) still remains the fourth most common cancer and the second most common cause of cancer-related deaths worldwide. Due to the limited treatment options, at present, prevention is likely to be the only effective means of controlling this disease. The success of a prevention strategy depends upon the understanding of etiological and pathogenic mechanisms underlying gastric carcinogenesis. The etiology of GC is multi-factorial, however, in the recent years, mounting evidence suggests that environmental factors play a key role. The most important environmental factors implicated in the pathogenesis of GC are diet and H pylori infection. Thus, modifications in lifestyle and dietary habit associated with eradication of H pylori infection could hypothetically represent the most promising potential targets for GC prevention. In this review we will address the evidence and the controversies on the role of these agents in non-cardia GC by focusing on retrospective and prospective observational studies and interventional trials.

Key Words: Gastric cancer, H pylori, Diet, Observational studies, Interventional dietary trials


Citation: Rocco A, Nardone G. Diet, H pylori infection and gastric cancer: Evidence and controversies. World J Gastroenterol 2007; 13(21): 2901-2912
INTRODUCTION

Despite the decreasing incidence and mortality rates observed worldwide over the last 50 years, gastric cancer (GC) still ranks as one of the most frequent and lethal cancers worldwide[1]. Today, GC is the fourth leading cancer type in incidence accounting for almost a million new cases diagnosed annually (International Agency for the Research on Cancer-IARC 2002)[2]. At present, primary or secondary prevention are likely to be the most effective means of reducing the incidence of and mortality from this disease. However, to be successful, this strategy depends upon knowledge of the etiologic factors involved in gastric carcinogenesis.

Topographically, GC may arise in the cardia of the stomach or more distally (non-cardia cancer)[3]. Besides the individual genetic susceptibility, epidemiological data suggest that environmental factors are the predominant cause of this disease even if the etiology and possibly the pathogenesis of these two types of cancer may be completely different[2,3].

The most important factors thought to be responsible for non-cardia GC development are diet and H pylori infection. In this review we will address the evidence of and the controversies on the role of these agents in non-cardia GC by focusing on retrospective and prospective observational studies and interventional trials.

DIET AND GASTRIC CANCER

The relationship between diet and cancer has been clearly demonstrated since the 1930s, in a series of experimental classical studies in which severe caloric restriction markedly reduced the occurrence of cancer in rodents[4]. In 1982 the World Health Organization (Food & Agriculture Organization) stated that eating habits were the main factor involved in GC risk.

Numerous epidemiology studies aimed at evaluating the role of diet in gastric carcinogenesis have been carried out both in high- and low-risk geographic areas (Table 1,Table 2 and Table 3). Despite the lack of homogeneity of age, ethnicity, socio-economic status of the populations studied as well as the different methodological approaches, one of the most remarkable features emerging from these studies is the consistency with which certain foods are reported as being important in the modulation of risk of developing GC.

Table 1 Epidemiological studies (population-based case-control) on dietary factors and gastric cancer.
AuthorYrGeographic areaCase/Control nIncreased riskDecreased risk
Risch HA51985Canada246/146Nitrite, chocolate, carbohydratesFiber, Vit. C
Buiatti E61990Italy1016/1159Nitrites, proteinVit. C, β-carotene, α-tocopherol, vegetable fat
Graham S71990USA293/293Sodium, fat, retinolβ-Carotene, raw vegetables, onions, cucumbers
Ramon JM81993Spain117/234--Vit. A, Vit. C
Kaaks R91998Belgium301/2851Vit. A, Vit. B12, mono, disaccharidesPolyunsaturated fat, Vit. C/B1-B2-B6, C/A
Lopez-Carrillo L101999Mexico220/752Protein, saturated fat, cholesterolPolyunsaturated fat, fiber, Vit. E
Mathew A112000India194/305Rice, spicy foods, chili, high-temperature food--
Palli D122001Italy382/561Protein, nitrite, sodiumVit. C/B6, β-carotene, α-tocopherol, nitrates
Mayne ST132001USA352/687Animal protein, cholesterol, Vit. B12, nitriteFiber, β-carotene, folate, Vit. C
Jedrychowski W142001Poland80/--CarbohydratesVit. E, β-carotene
Hamada GS152002Brazil97/192BeefFruits
Chen H162002Nebraska124/449Saturated fatFiber, Vit. C
Hara M172003Japan149/287--Cruciferous vegatables, mushrooms
Nomura AM182003Hawaii300/446Processed meat, baconβ-carotene, Vit. C, Vit. E, folate
Lagiou P192004Greece110/100--Flavanone
De Stefani E202004Uruguay240/960Salted-stewed meat, rice, tuberVegetables, legumes, fruit, black tea
Table 2 Epidemiological prospective cohort studies on association between dietary factors and GC (1990-2004).
AuthorYrGeographic areaSubjects nFU yrIncreased riskDecreased riskNo effect
Chyou PH211990USA (Hawaii)800618--Green/ cruciferous vegetables, fruit--
Kneller RW221991USA1763320Carbohydrates, salted-fish, bacon, cooked cereals, milk----
Kato I231992Japan97536Alcohol, broiling meatFruit--
Nomura A241995USA (Hawaii)800625--Fruit, vegetablesAlcohol
Dorant E251996The Netherlands1208523.3--OnionsLeek, garlic
Goldbohm RA261996The Netherlands1208524.3----Black tea
Ocke MC271998The Netherlands1276325--Vegetables, fruit, fiber-rich cereals--
Terry P281998Sweden1194625--Fruit, vegetables--
Galanis DJ291998USA (Hawai)1190714.8CoffeeFruit, raw vegetablesPickled vegetables, dried/salted fish
Knekt P301999Finland998524----Nitrates, nitrites, NDMA
Jansen MC311999Netherlands1200025Refined grainsFruitVegetables
Whole grain
Botterweck AA322000The Netherlands1208526.3Retinol, caroteneVit. CFolate, Vit. E, carotene, lycopene, fibers, Vit. A, BHA, BHT
Tsubono Y332001Japan263118----Green tea
McCullough ML342001USA120000014Vegetables1Vegetables, citrus fruit, whole grain2--
Nagata C352002Japan333047--Soy products--
Ngoan LT362002Japan1300010Processed meat, cooking oil, pickled food, soupGreen/yellow vegetables, fruit, cuttle-fish, tofu, potatoes--
Kobayashi M372002Japan3999310--Fruit, vegetables--
Masaki M382003Japan576510Meat patternVegetable and fruit pattern--
Rice/snack patternWestern breakfast pattern
Khan MM392004Japan315818Carbonated drink/juice1Miso soup2--
Kim MK402004Japan42 11210Traditional dietary patternHealthy dietary pattern1--
Sasazuki S412004Japan72 74311--Green tea1--
1EPIC42-442006Europe521 4576.6Red and processed meat, ENOCPlasma vitamin C Total vegetable intake Onion, garlicDietary Vitamin C
Table 3 Randomised controlled dietary intervention trials for prevention of stomach cancer.
AuthorYrGeographic areaSubjects nDietary interventionIntervention (yr)FU (yr)Results
Wang GQ671994China29584retinol/zinc; riboflavin/niacin; Vit. C/molybdenum; carotene/Vit.E/selenium5.255.25↓ gastric cancer mortality
Varis K681998Finland29133α-tocopherol 50 mg/d; β-carotene 20 mg/d;55= gastric cancer incidence
Malila N692002Finland29133α-tocopherol 50 mg/d; β-carotene 20 mg/d5-88= gastric cancer incidence
Zhu S702003China216Folate 20 mg/d + Vit. B12 1 mg/mo Natural β-carotene 30 mg/d Synthetic β-carotene 30 mg/d28No change cancer incidence ↓ precancerous lesions
Li H712004China2526Synthetic allitridum 200 mg + selenium 100 mg25No change cancer incidence
Observational epidemiology studies

The majority of the case-control epidemiological studies[5-20] have shown that high intake of salted, pickled or smoked foods, as well as dried fish and meat and refined carbohydrates significantly increases the risk of developing GC while fiber, fresh vegetables and fruits were found to be inversely associated with GC risk (Table 1).

High consumption of refined carbohydrates has been shown to be associated with a significant increased risk of developing GC with an estimated odds ratio (OR) ranging from 1.5[5] to 8.73/100 mg of daily intake[14]. The increased trend in risk appeared particularly high in females (OR highest quartile of consumption frequency [Q4] vs lowest quartile [Q1] 14.8)[28]. High consumption of saturated fat and cholesterol enhanced the risk of cancer for intestinal type GC (OR Q4 vs Q1 4.37; 95% CI 1.89-10.12 for saturated fat and OR Q4 vs Q1 2.39; 95% CI 1.23-4.64 for cholesterol)[10].

The analysis of dietary micronutrients (vitamin C, vitamin E, carotenoids, fiber, flavonoids and selenium) commonly held to be protective against GC yielded conflicting results. While evidence on the protective effect of beta-carotene has been very consistent, the approximate halving risk associated with vitamin C intake, reported in some studies (OR ranging from 0.3; 95% CI 0.1-0.8 to 0.60; CI 0.41-0.88)[8,9,12,13] has not been confirmed in others[5,18,19].

Epidemiological approaches of case-control design could, in part, account for these contrasting results. Indeed, observational case-control studies are biased by the retrospective assessment of exposure to dietary risk factors: the onset of the symptoms affects the dietary habit and it is difficult to determine it following the diagnosis of cancer (“recall-bias”).

Observational cohort studies, in which the evaluation of diet is unaffected by symptoms, should ideally provide much more reliable evidence. Analysis of the data obtained in 21 studies involving a total of 1 651 231 individuals, followed for periods ranging between 3.3 and 25 years[21-44], substantially confirmed the significant increased risk of developing GC due to high intake of total carbohydrates, salted fish, processed meat, refined grains and saturated fat[22,31,36].

Two Japanese studies based on the analysis of dietary patterns failed to demonstrate an increased risk of GC in middle-aged males with a “meat” or “rice” prevalent diet (relative risk [RR] 1.00; 95% CI 0.55-1.10 and RR 1.00; 95% CI 0.52-1.19, respectively)[38] while the “traditional pattern” was a risk factor for both genders (RR 2.88; 95% CI 1.76-4.72 for males and RR 2.40; 95% CI 1.32-4.35 for females)[40]. A large prospective study on diet and cancer carried out on 521 457 individuals aged 35-70 years recruited in 10 European countries (EPIC-European Prospective Investigation into Cancer and Nutrition study), by analyzing 314 incident cases of GC that had occurred after 6.6 average years of follow-up, reported a significant increase of non-cardia cancer risk associated with intake of total meat (calibrated HR per 100 g/d increase 3.52; 95% CI 1.96-6.34), red meat (calibrated HR per 50 g/d increase 1.73; 95% CI 1.03-2.88), and processed meat (calibrated HR per 50-g/d increase 2.45; 95% CI 1.43-4.21). The risk of developing GC was particularly high in H pylori antibody-positive subjects[42]. Similar results were obtained for the endogenous formation of nitroso compounds (ENOC). ENOC was significantly associated with non-cardia cancer risk (HR 1.42; 95% CI 1.14-1.78 for an increase of 40 mg/d) especially in those cases with H pylori infection (P for interaction = 0.09)[43].

Data on the protective role of fresh fruit and vegetables against stomach cancer were somewhat controversial. The analysis of 11 546 individuals included in the Swedish Twin Registry demonstrated that the lowest compared to the highest fruit and vegetable intake had a RR of developing GC of 5.5 (95% CI 1.7-18.3) with a statistically significant dose-risk trend (P < 0.05)[28]. The Japan-Hawaii Cancer Study on 8006 Hawaiian men of Japanese ancestry reported that all types of vegetables were protective against GC. Subjects in the group of highest vegetable consumption (≥ 80 g/d) had a RR of developing GC of 0.6 (95% CI 0.3-0.9) compared to non-consumers[21,24]. Green and yellow vegetables showed the highest protective effect against GC (RR 0.4; 95% CI 0.2-0.9 and 0.64; 95% CI 0.45-0.92, respectively)[36,37].

On the other hand, the Seven Countries Study Research Group found no association between total vegetable intake and GC risk[31]. Finally, the Cancer Prevention Study, on a cohort of 1.2 million United States individuals, demonstrated a reduced risk in males (RR 0.79; 95% CI, 0.67-0.93) and an unexpected increased risk in females (RR 1.25; 95 CI 0.99-1.58)[34].

Data from EPIC study analysing the association of plasma and dietary vitamin C levels with the risk of GC, after adjustment by body mass index, total energy intake, smoking (status, duration and intensity) and H pylori status demonstrated no association with GC risk for dietary vitamin C. In contrast an inverse GC risk was observed in the highest versus lowest quartile of plasma vitamin C (OR 0.55 95% CI 0.31-0.97). The inverse association was more pronounced in subjects consuming higher levels of red and processed meats, a factor that may increase endogenous N-nitroso compound production. The protective effect of plasma vitamin C was independent of GC anatomical sub-site (cardia vs non-cardia) or histological sub-type (diffuse vs intestinal) or presence of H pylori infection[44].

Several epidemiology studies specifically addressed the association of garlic consumption and risk of stomach cancer. Six case-control studies analyzing on the whole 3209 GC cases and 7600 controls, suggested a protective effect of high intake of raw and/or cooked garlic for GC (OR ranging from 0.3 to 0.89; 95% CI 0.12-0.77 and 0.64-1.24, respectively)[6,45-49]. Only one cohort study (based on a case-cohort approach) compared the intake of garlic supplements of 152 subjects who developed GC during a 3.3 years follow-up with that of a random sample from the entire cohort who did not developed any type of cancer. Beside the expectative, garlic supplements slightly increased the risk of developing GC (RR 1.27; 95% CI 0.6-2.6)[25].

Tea is one of the most popular beverages in the world and the consumption of tea has been hypothesized to be associated with a decreased risk of GC[50]. The catechins and their strong antioxidant and anti-angiogenic activity as well as their potential to inhibit cell proliferation and modulate carcinogen metabolism could be responsible for the biological benefits of tea[51,52].

However, epidemiological studies analyzing the relationship between tea and GC risk yielded conflicting results[47,50,53-62]. Among the case-control studies, eight showed that high consumers of green tea (> 10 cups/d) had a statistically significant reduction of the risk of developing GC[47,50,53-58], three studies failed to demonstrate any significant decrease of the GC risk[59-61] and the remaining showed an opposite result[62]. The majority of the prospective studies did not find an inverse association between tea consumption and the risk of GC[26,33,63,64]. In contrast, three studies[41,65,66] confirmed the protective role of tea against GC particularly for non-cardia GC (OR 0.51 95% CI 0.30-0.86) in the highest category of green tea consumption (≥ 5 cups/d vs≤ 1 cup/d)[41]. On the basis of this epidemiological evidence no convincing claims can be made with regard to the protective effect of garlic and tea on GC. However, low study power, variability in consumption categorization within studies and poor adjustment for potential confounders may limit the reliability of any conclusion regarding garlic and tea supplementation.

Interventional dietary trials for prevention of gastric cancer

Randomized clinical trials provide one of the most scientifically rigorous approaches for testing hypotheses emerging from epidemiological and experimental studies and represent the ideal strategic approach to evaluate inhibition of cancer development by preventive measures.

The most relevant finding reported by the observational studies analyzing the role of diet in GC development concerned the inverse association between fruit and vegetable intake and GC risk. These foods contain phytochemicals endowed with anticancer and anti-inflammatory properties and are rich in ascorbic acid, beta-carotene and other carotenoids offering many health benefits. Dietary interventional trials for stomach cancer prevention have, therefore, been based mainly on long-term supplementation with anti-oxidant micronutrients given alone or in combination (beta-carotene, vitamin A, vitamin C, vitamin E, selenium)[67-71]. However, all interventional studies but one[70] failed to demonstrate any significant change in the risk of GC in subjects receiving anti-oxidant supplementation (Table 3). The most important study, the “General Population Trial” involving 29 584 subjects residing in Linxian, China, and followed for 5.25 years, demonstrated no statistically significant reduction in the prevalence of GC for any of the interventional arms, even though, a reduction in total mortality, total cancer mortality and stomach cancer mortality was found among those receiving beta-carotene, vitamin E and selenium[67]. Similar results were obtained in the Alpha-Tocopherol Beta-Carotene (ATBC) Cancer Prevention Study conducted in Southwest Finland and involving 29 133 middle-aged male smokers observed between 1985 and 1993[68,69]. Long-term supplementation with alpha-tocopherol (50 mg/d) and/or beta-carotene (20 mg/d), both at five- and six-year follow-up, had no significant effect on the overall incidence of GC (RR 1.21 95% CI 0.85-1.74 for alpha-tocopherol and RR 1.26 95% CI 0.88-1.80 for beta-carotene). Paradoxically, a subgroup analysis according to histological type suggested an increased risk for beta-carotene on intestinal type cancer (RR 1.59 95% CI 0.99-2.56)[68,69]. Finally, another study involving 216 atrophic gastritis patients treated with folic acid and/or beta-carotene supplementation and followed for a period of 8 years failed to demonstrate any significant reduction in the incidence of GC. However, folic acid significantly improved gastric mucosa lesions by reversing gastric atrophy, inflammation and intestinal metaplasia and dysplasia at the end of follow-up[70].

On the other hand, a double-blinded interventional study involving 2526 subjects at risk of developing GC and 2507 controls from a Chinese province, demonstrated, in the first five years of follow-up, a significant reduction in the morbidity rates of malignant gastric tumours in the intervention group treated with large doses of synthetic allitridum associated with microdoses of selenium for a period of 3 years (RR 0.48; 95% CI 0.21-1.06 for the entire population and RR 0.36; 95% CI 0.14-0.92 for male group)[71].

H PYLORI INFECTION AND GC RISK

Since the incidental discovery in 1983, the association of H pylori with GC has become a hot topic of gastroenterological studies. Just a decade later, a large cross-sectional study (the EUROGAST study) involving 17 populations from 13 different countries (Unites States, Japan and 11 European countries), concluded that H pylori-infected patients had six-fold increased risk of GC compared with uninfected subjects[72]. In 1994, despite some controversial opinion, the International Agency for Research on Cancer declared H pylori to be a groupIhuman carcinogen for gastric adenocarcinoma[73]. The statement was mainly based on epidemiological investigations since no experimental studies had been performed at that time to prove the causal link between H pylori and GC. Currently, although substantial evidence supports the role of H pylori infection in GC development, the magnitude of the risk of GC associated with infection remains unclear.

Many epidemiological studies have been conducted in an attempt to address this issue (Tables 4 and 5). Retrospective case-control studies analyzing on the whole 8306 GC cases and 15 884 controls reported an increased risk of developing GC for patients with H pylori infection (OR ranging from 1.10; 95% CI 0.43-2.86 to 18.3; 95% CI 2.4-136.7)[74-123]. However, five studies failed to demonstrate any significant risk associated to previous or concurrent H pylori infection[78,79,105,116,118]. Retrospective case-control studies are limited “per se” by several biases. In GC patients (cases) H pylori infection is usually assessed after the development of cancer, but advanced gastric diseases can be characterized by the loss of infection resulting in a fall of the circulating anti-H pylori antibodies. In addition, the type of control population and the absence of adjustment for confounding factors (age, sex, smoking, and dietary habit) can hamper the statistical evaluation leading, to over- or underestimation of the real risk linked to H pylori infection.

Table 4 Epidemiological studies (case/control) on association between H. pylori infection and GC risk (1990-2005).
AuthorYrGeographic areaCase/Control nOR (95% CI)Detection of infection
Loffeld RJ741990The Netherland91/4012.04 (1.07-3.91)Serology
Caruso ML751990Italy44/224.72 (1.32-19.04)Histology
Talley NJ761991USA69/2521.63 (0.79-3.37)Serology
Sipponen P771992Finland54/842.21 (1.01-4.91)Serology, histology
Kuipers EJ781993The Netherlands116/1160.86 (0.44-1.68)Serology
Estevens J791993Portugal80/800.54 (0.24-1.19)Serology
Blaser MJ801993Japan29/582.14(0.72-6.40)Serology
Tatsuta M811993Japan41/192.42 (0.69-8.66)Biopsy culture
Buruk F821993Turkey46/401.89 (0.69-5.21)Serology
Hansson LE831993Sweden112/1032.60 (1.35-5.02)Serology
Archimandritis A841993Greece47/501.23 (0.51-2.95)Serology
Lin JT851993China, Taiwan143/8231.42 (0.97-2.08)Serology
Hu PJ861994China51/1025.10 (1.70-15.5)Serology, histology
Sipponen P871994Finland243/14081.31 (0.99-1.74)Histology
Asaka M881994Japan213/2132.55 (1.48-4.44)Serology
Kikuchi S891995Japan105/10213.3 (5.3-35.6)Serology
Rudi J901995Germany111/1111.39 (0.82-2.36)Serology
Fukuda H911995Japan282/7671.13 (0.81-1.58)Serology
Menegatti M921995Italy307/1623.66 (2.33-5.74)Serology, histology
Asaka M931995Japan109/1092.40 (1.20-4.80)Serology
Hatz RA941996Germany95/932.03 (1.05-3.92)Serology
Shibata T951996Japan50/501.10 (0.43-2.86)Histology
Kato S961996Japan82/1511.12 (0.60-2.07)Serology
Kokkola A971996Finland50/223.27 (1.42-7.52)Histology
Menegatti M981996Italy148/544.02 (1.99-8.17)Serology, histology
Sivaprakash R991996India75/751.91 (1.00-3.67)Serology, biopsy culture
Kim HY1001997Korea160/1601.39 (0.89-2.17)Histology
Miehlke S1011997Germany215/21516.7 (CI 9.6-29.1)Histology, 13C-UBT
Shi Y1021997China110/1253.30 (1.90-5.9)Serology
Barreto-Zuniga R1031997Japan55/753.00 (1.69-5.33)Serology
Martin-de-Argila C1041997Spain48/503.01 (1.02-8.86)Serology
Azuma T1051998Japan82/1670.97 (0.54-1.75)Serology
Komoto K1061998Japan105/1055.60 (2.33-13.4)Serology, histology
Wu MS1071998Taiwan135/1352.43 (1.29-4.65)Serology
Whiting JL1081998UK154/1541.67 (1.01-2.75)Serology
Lee BM1091998Korea175/1135.20 (3.10-8.70)CLO test
Kikuchi S1101999Japan103/10115.0 (6.4, 35.2)Serology
Zhang ZF1111999USA134/6511.2 (2.5-50.3)Histology
Cai L1122000China101/1013.45 (0.90-13.2)Serology
Enroth H1132000Sweden72/3242.1 (1.1-3.9)Serology, histology
Chang WK1142001Korea136/1361.82 (1.10-3.00)Serology
Ekstrom AM1152001Sweden298/2445.0 (1.10-23.6)Serology
Fujioka N1162001Brazil93/1861 228/22620.80 (0.47-1.36) 0.84 (0.54-1.30)Serology
Konturek SJ1172002Poland337/3372.59 (1.61-4.22)Serology
Sriamporn S1182002Thailand111/2320.60 (0.40-1.0)Serology
Wu AH1192003USA127/3561.85 (1.03-3.32)Serology
Brenner H1202004Germany68/36018.3 (2.4-136.7)Serology
Machida-Montani A1212004Japan122/2358.20 (3.70-18.2)Serology
Kato M1222004Japan2503/65782.47 (2.19-2.79)Serology
Nomura AM1232005Hawaii299/3364.86 (5.90-8.13)Serology
Table 5 Epidemiological studies (cohort nested case-control study) on association between H pylori infection and GC risk.
AuthorYrGeographic areaCase/Control nOR (95% CI)Mean follow-up (yr)
Nomura AM1241991USA109/1096.0 (2.1-17.3)12
Parsonnet J1251991USA109/1093.6 (1.8-7.3)14.2
Forman D1261991England116/4842.7 (1.0-7.9)15
Parsonnet J1271993USA136/1362.62 (1.47-4.69)21
Blaser MJ1281995USA102/1021.45 (0.76-2.80)3
Lin JT1291995China, Taiwan29/2201.13 (0.81-1.58)13
Aromaa A1301996Finland80/1461.50 (0.70-3.22)6
Webb PM1311996China87/2610.93 (0.57-1.54)40
Siman JH1321997Sweden56/2245.00 (2.20-11.5)5.7
Watanabe Y1331997Japan45/2251.84 (1.54-5.72)8
1Yuan JM°1341999China188/5481.84 (1.08-3.11)12
Hansen S1351999Norvay208/2085.15 (2.83-9.37)13
You WC1362000China34/25941.8 (1.20-2.60)4.5
Tulinius H1372001Iceland23/1281.16 (1.05-1.28)20
Siman JH1382001Sweden56/2245.0 (2.2-11.2)5.7
Limburg P1392001China92/1922.29 (1.26-4.14)15
Nomura AM1402002Hawaii261/2612.70 (1.30-5.6)25
Kosunen TU1412005Finland363/48542.49 (1.86-3.34)24
Shin A1422005Korea86/3441.06 (0.80-1.40)2.6
Knekt P1432006Finland225/4353.12 (1.97-4.95)15

Prospective studies, by contrast, should be more informative because they use internal control “nested” within a cohort. The infection is assessed by examining blood samples taken years before the onset of clinical disease, so that the enrollment of the studied population did not suffer of selection bias. All cohort studies[124-143] reported an increased risk of developing GC associated to H pylori infection (OR ranging from 1.06; 95% CI 0.80-1.40 to 6.0; 95% CI 2.1-17.3) (Table 5). Only one study conducted in a high-risk population from Shanghai, China, failed to demonstrate an association between H pylori infection and the subsequent risk of GC[131]. However, an update of the results at longer follow-up and by using an enzyme-linked immunosorbent assay (ELISA) based on strains validated among the Shanghai residents showed a statistically significant association between H pylori seropositivity and GC risk (OR 1.84; 95% CI, 1.08-3.11 raising to 3.74; 95% CI 1.51-9.30 among subjects followed for 5 or more years after enrolment)[134].

A meta-analysis of cohort and case-control studies evaluated that the summary OR for GC in H pylori infected patients was 1.92 (95% CI 1.32-2.78), 2.24 (95% CI 1.15-4.4), and 1.81 (95% CI, 1.16-2.84) for all studies, cohort, and case-control studies, respectively. The risk of developing GC was greatest in younger patients (OR 9.29 at age < 29 years) and was equally associated with the intestinal or diffuse type GC[144]. A combined analysis of 12 case-control studies (6 from Europe, 4 from Asia, 2 from the United States) nested with prospective cohorts and involving 1228 GC cases and 3406 controls, revealed that the association of H pylori infection with GC was restricted to non-cardia cancers (OR 2.97; 95% CI 2.3-3.7), and was stronger when blood samples for H pylori serology were collected ten years or more before cancer diagnosis (OR 5.9; 95% CI 3.4-10.3)[145]. However, the most powerful evidence comes from a prospective study on 1526 Japanese patients followed for approximately 7.8 years. GC developed in 36 out of 1246 H pylori-positive patients (2.9%) in contrast to none of the 280 non-infected subjects[146].

Infection with cagA-positive strains further increases the risk of developing GC. According to a recent meta-analysis of 2284 cases and 2770 controls, infection with cag-A-positive strains increased the risk of developing GC up to 1.64-fold (95% CI 1.21-2.24) for all sites GC and 2.01-fold (95% CI 1.21-3.32) for non-cardia GC[147].

The close relationship between H pylori infection and GC leads to the critical question of whether antimicrobial therapy can be considered for GC chemoprevention. A prospective, randomized, placebo-controlled, population study carried out in a high-risk area of China involving 1630 subjects observed from 1994 to 2002 reported a comparable incidence of GC in the subjects receiving H pylori eradication treatment and those receiving placebo. However, eradication of H pylori significantly decreased the development of GC in a subgroup of H pylori carriers not presenting precancerous lesions[148]. On the other hand, a randomized, controlled chemoprevention trial conducted in subjects with confirmed histological diagnoses of multifocal, non-metaplastic atrophy and/or intestinal metaplasia, assigned to receive anti-H pylori triple therapy and/or dietary supplementation (ascorbic acid, beta-carotene, or their corresponding placebos), demonstrated a significant regression rate of the lesions for all three basic interventions (RR 4.8 95% CI 1.6-14.2 for anti-H pylori treatment; 5.1, 95% CI 1.7-15.0 for beta-carotene treatment, and 5.0; 95% CI 1.7-14.4 for ascorbic acid treatment in subjects with atrophy and 3.1; 95% CI 1.0-9.3; 3.4; 95% CI 1.1-9.8, and 3.3; 95% CI 1.1-9.5 in subjects with intestinal metaplasia)[149].

INTERPLAY BETWEEN H PYLORI INFECTION AND DIET

A synergistic interaction between H pylori infection and diet in GC has been suggested[150]. One possible mechanism by which H pylori exerts its “carcinogenic” potential is the greater likelihood of malignant transformation due to inflammatory responses of the gastric epithelium. The generation of reactive oxygen species (ROS) and the increased level of nitric oxide (NO) synthase associated with the mucosal colonization by H pylori cause DNA mutations which may be the initial step in the genetic alterations of gastric epithelial cells[151-153]. Another possible explanation is that the H pylori-related inflammation induces predisposing morphological changes in the gastric mucosa such as atrophy and intestinal metaplasia[154]. These latter conditions decrease the acidity in the stomach increasing the endogenous formation of nitrosamides, the main subset of N-nitroso compounds[155]. Nitrosamides, spontaneously formed in the stomach from the nitrite and amides, do not require enzymes but depend on the presence of nitrites and are favored by a high pH. Thus, the ability of the host to reduce nitrate to nitrite and the dietary intake of nitrate and amine are critical for the onset of the gastric carcinogenic process. This hypothesis links the theory of “N-nitroso compounds-mediated GC risk” with that of the “H pylori-related GC risk” suggesting an “integrated model” of gastric carcinogenesis. However, even if the synergistic interaction between diet and H pylori infection is biologically plausible, only a few epidemiological studies have simultaneously evaluated the role of H pylori infection and dietary habits in relation to GC risk. Furthermore, the results of these studies were conflicting (Table 6)[118,121,156,157]. A case-control study conducted in Thailand analyzing both the effect of dietary pattern and H pylori infection found an increased risk of GC associated with a high intake of salt (OR 1.8; 95% CI 1.1-3.0) and fermented foods (OR 1.9; 95% CI 1.1-3.3)[118]. In contrast, a weak negative association was found between GC risk and vegetable and fruit intake and no association between H pylori infection and GC risk (OR 0.6; 95% CI 0.4-1.0)[118]. Likewise, a study evaluating the role of H pylori infection and capsaicin consumption on the risk of GC demonstrated an increased risk (OR 1.71; 95% CI: 0.76-3.88) in high-level consumers of capsaicin (90-200 mg/d) as compared to low-consumers (0-29.9 mg/d). However, this effect was independent of H pylori status and was higher for diffuse type GC (OR 3.64; 95% CI 1.09-12.2) compared to the intestinal type (OR 1.36; 95% CI 0.31-5.89)[157]. Lastly, Machida-Montani et al[121] found a close correlation between GC and H pylori infection (OR 8.2; 95% CI 3.7-18.2), frequent intake of fermented soy bean soup (OR 2.1; 95% CI 0.9-5.1), and rice (OR 2.5; 95% CI 1.0-6.1) but no significant interaction between diet and H pylori infection. In contrast, in a Korean hospital-based case-control study, subjects with H pylori infection and high salt intake had a 10-fold higher risk of developing GC than subjects without H pylori infection and low salt intake (P = 0.047)[156].

Table 6 Epidemiological studies (hospital-based case-control) on association between dietary factors and H pylori infection and gastric cancer risk.
AuthorYrGeographic areaCase/Control nIncreased riskDecreased riskH pylori risk
Sriamporn S1182002Thailand131/262Salt, fermented foodsVegetables, fruitIndependent
Lee SA1562003Korea69/199Salt, kimchi, salt-fermented fishVegetables, fruit, soybean curds, brothIncreased
Lopez-Carrillo L1572003Mexico234/468Capsaicin--Independent
Machida-Montani A1212004Japan122/235Fermented soy bean, rice--Independent
DISCUSSION

GC develops through a multistage process which may span ≥ 20 years[154]. The long latency period hypothetically provides wide opportunities for intervention to prevent cancer development. However, several questions need to be answered before the results of epidemiological and interventional studies can be extended to the clinical setting.

Firstly, GC comprises at least two main entities, the intestinal and the diffuse type, which differ considerably from an epidemiological, clinical and molecular point of view[158]. Based on epidemiological evidence, the intestinal type, preceded by precancerous lesions, seems more closely influenced by environmental factors while the latter recognizes mainly a “genetic” substrate. However, only a few studies have focused on the nutritional pattern in relation to the histotype of GC[6,159-161]. Even hampered by the small number of cases studied, the results strongly suggest that the dietary risk factors are common to both types of GC while the protective factors play a more important role in preventing the intestinal type. Secondly, trials directly evaluating cancer development as target require very large numbers of subjects to be followed for decades. Trials with smaller groups of subjects followed for shorter periods and focusing on the intermediate steps of the gastric carcinogenic process may hypothetically obtain information on the possible inhibition of cancer development. However, only the “intestinal type” cancer recognizes a precancerous “cascade” of events and only a small subset of patients with precancerous lesions develop GC[154]. Thus, very large number of subjects for many years would need to be followed to obtain conclusive results. Finally, due to the” synergistic” interplay between diet and H pylori infection, H pylori should always be properly considered.

In conclusion, although GC is a disease of genes, mainly triggered by H pylori-related mucosal inflammation, overwhelming evidence suggest that diet and lifestyle factors are important causes leading to cancer. Indeed, the progressive decline in GC incidence observed between 1930s and 1980s, before the discovery of H pylori, can be, without doubt, related to improvement of diet and spread use of refrigerators. On the other hand, data suggesting that H pylori eradication may reduce the risk of developing GC need still to be confirmed by large-scale population studies[162]. One study that economically modelled the cost of screening per year of life saved estimated that in selected populations such as Japanese American, serological screening for H pylori at age 50 years was more beneficial than breast cancer screening[163]. However, there are insufficient data to recommend general screening for H pylori of asymptomatic patients to prevent GC. The decision to screen should be based on individual risk factors such as race, and family history of GC[164].

At present, even if foods and food components acting as risk or protective factors for GC still remain to be fully defined, a diet rich in fruit, vegetables and cereals and poor in meat, fat and salt has a good prophylactic potential for cancer and many other chronic diseases of lifestyle i.e. coronary heart disease, hypertension, obesity and diabetes. Thus, “diet for cancer prevention” can be proposed as a general role of well-being and can represent the basis for a rational health policy.

Footnotes

S- Editor Liu Y L- Editor Alpini GD E- Editor Wang HF

References
1.  Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-1504.  [PubMed]  [DOI]
2.  American Cancer Society.  Estimated New Cancer Cases and Deaths by Sex for all Sites. American Cancer Society, United States. http: //www.cancer.org/statistics/cff2000/data/newCaseSex.html Available from: http: //www.cancer.org/statistics/cff2000/data/newCaseSex.html.  [PubMed]  [DOI]
3.  Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol. 1996;23:281-291.  [PubMed]  [DOI]
4.  McCay CM, Crowell MF, Maynard LA. The effect of retarded growth upon the length of life span and upon the ultimate body size. 1935. Nutrition. 1989;5:155-171; discussion 172.  [PubMed]  [DOI]
5.  Risch HA, Jain M, Choi NW, Fodor JG, Pfeiffer CJ, Howe GR, Harrison LW, Craib KJ, Miller AB. Dietary factors and the incidence of cancer of the stomach. Am J Epidemiol. 1985;122:947-959.  [PubMed]  [DOI]
6.  Buiatti E, Palli D, Bianchi S, Decarli A, Amadori D, Avellini C, Cipriani F, Cocco P, Giacosa A, Lorenzini L. A case-control study of gastric cancer and diet in Italy. III. Risk patterns by histologic type. Int J Cancer. 1991;48:369-374.  [PubMed]  [DOI]
7.  Graham S, Haughey B, Marshall J, Brasure J, Zielezny M, Freudenheim J, West D, Nolan J, Wilkinson G. Diet in the epidemiology of gastric cancer. Nutr Cancer. 1990;13:19-34.  [PubMed]  [DOI]
8.  Ramón JM, Serra-Majem L, Cerdó C, Oromí J. Nutrient intake and gastric cancer risk: a case-control study in Spain. Int J Epidemiol. 1993;22:983-988.  [PubMed]  [DOI]
9.  Kaaks R, Tuyns AJ, Haelterman M, Riboli E. Nutrient intake patterns and gastric cancer risk: a case-control study in Belgium. Int J Cancer. 1998;78:415-420.  [PubMed]  [DOI]
10.  López-Carrillo L, López-Cervantes M, Ward MH, Bravo-Alvarado J, Ramírez-Espitia A. Nutrient intake and gastric cancer in Mexico. Int J Cancer. 1999;83:601-605.  [PubMed]  [DOI]
11.  Mathew A, Gangadharan P, Varghese C, Nair MK. Diet and stomach cancer: a case-control study in South India. Eur J Cancer Prev. 2000;9:89-97.  [PubMed]  [DOI]
12.  Palli D, Russo A, Decarli A. Dietary patterns, nutrient intake and gastric cancer in a high-risk area of Italy. Cancer Causes Control. 2001;12:163-172.  [PubMed]  [DOI]
13.  Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, Farrow DC, Schoenberg JB, Stanford JL, Ahsan H. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:1055-1062.  [PubMed]  [DOI]
14.  Jedrychowski W, Popiela T, Steindorf K, Tobiasz-Adamczyk B, Kulig J, Penar A, Wahrendorf J. Nutrient intake patterns in gastric and colorectal cancers. Int J Occup Med Environ Health. 2001;14:391-395.  [PubMed]  [DOI]
15.  Hamada GS, Kowalski LP, Nishimoto IN, Rodrigues JJ, Iriya K, Sasazuki S, Hanaoka T, Tsugane S. Risk factors for stomach cancer in Brazil (II): a case-control study among Japanese Brazilians in São Paulo. Jpn J Clin Oncol. 2002;32:284-290.  [PubMed]  [DOI]
16.  Chen H, Tucker KL, Graubard BI, Heineman EF, Markin RS, Potischman NA, Russell RM, Weisenburger DD, Ward MH. Nutrient intakes and adenocarcinoma of the esophagus and distal stomach. Nutr Cancer. 2002;42:33-40.  [PubMed]  [DOI]
17.  Hara M, Hanaoka T, Kobayashi M, Otani T, Adachi HY, Montani A, Natsukawa S, Shaura K, Koizumi Y, Kasuga Y. Cruciferous vegetables, mushrooms, and gastrointestinal cancer risks in a multicenter, hospital-based case-control study in Japan. Nutr Cancer. 2003;46:138-147.  [PubMed]  [DOI]
18.  Nomura AM, Hankin JH, Kolonel LN, Wilkens LR, Goodman MT, Stemmermann GN. Case-control study of diet and other risk factors for gastric cancer in Hawaii (United States). Cancer Causes Control. 2003;14:547-558.  [PubMed]  [DOI]
19.  Lagiou P, Samoli E, Lagiou A, Peterson J, Tzonou A, Dwyer J, Trichopoulos D. Flavonoids, vitamin C and adenocarcinoma of the stomach. Cancer Causes Control. 2004;15:67-72.  [PubMed]  [DOI]
20.  De Stefani E, Correa P, Boffetta P, Deneo-Pellegrini H, Ronco AL, Mendilaharsu M. Dietary patterns and risk of gastric cancer: a case-control study in Uruguay. Gastric Cancer. 2004;7:211-220.  [PubMed]  [DOI]
21.  Chyou PH, Nomura AM, Hankin JH, Stemmermann GN. A case-cohort study of diet and stomach cancer. Cancer Res. 1990;50:7501-7504.  [PubMed]  [DOI]
22.  Kneller RW, McLaughlin JK, Bjelke E, Schuman LM, Blot WJ, Wacholder S, Gridley G, CoChien HT, Fraumeni JF. A cohort study of stomach cancer in a high-risk American population. Cancer. 1991;68:672-678.  [PubMed]  [DOI]
23.  Kato I, Tominaga S, Matsumoto K. A prospective study of stomach cancer among a rural Japanese population: a 6-year survey. Jpn J Cancer Res. 1992;83:568-575.  [PubMed]  [DOI]
24.  Nomura AM, Stemmermann GN, Chyou PH. Gastric cancer among the Japanese in Hawaii. Jpn J Cancer Res. 1995;86:916-923.  [PubMed]  [DOI]
25.  Dorant E, van den Brandt PA, Goldbohm RA, Sturmans F. Consumption of onions and a reduced risk of stomach carcinoma. Gastroenterology. 1996;110:12-20.  [PubMed]  [DOI]
26.  Goldbohm RA, Hertog MG, Brants HA, van Poppel G, van den Brandt PA. Consumption of black tea and cancer risk: a prospective cohort study. J Natl Cancer Inst. 1996;88:93-100.  [PubMed]  [DOI]
27.  Ocké MC, Bueno-de-Mesquita HB, Feskens EJ, Kromhout D, Menotti A, Blackburn H. Adherence to the European Code Against Cancer in relation to long-term cancer mortality: intercohort comparisons from the Seven Countries Study. Nutr Cancer. 1998;30:14-20.  [PubMed]  [DOI]
28.  Terry P, Nyrén O, Yuen J. Protective effect of fruits and vegetables on stomach cancer in a cohort of Swedish twins. Int J Cancer. 1998;76:35-37.  [PubMed]  [DOI]
29.  Galanis DJ, Kolonel LN, Lee J, Nomura A. Intakes of selected foods and beverages and the incidence of gastric cancer among the Japanese residents of Hawaii: a prospective study. Int J Epidemiol. 1998;27:173-180.  [PubMed]  [DOI]
30.  Knekt P, Järvinen R, Dich J, Hakulinen T. Risk of colorectal and other gastro-intestinal cancers after exposure to nitrate, nitrite and N-nitroso compounds: a follow-up study. Int J Cancer. 1999;80:852-856.  [PubMed]  [DOI]
31.  Jansen MC, Bueno-de-Mesquita HB, Räsänen L, Fidanza F, Menotti A, Nissinen A, Feskens EJ, Kok FJ, Kromhout D. Consumption of plant foods and stomach cancer mortality in the seven countries study. Is grain consumption a risk factor? Seven Countries Study Research Group. Nutr Cancer. 1999;34:49-55.  [PubMed]  [DOI]
32.  Botterweck AA, Verhagen H, Goldbohm RA, Kleinjans J, van den Brandt PA. Intake of butylated hydroxyanisole and butylated hydroxytoluene and stomach cancer risk: results from analyses in the Netherlands Cohort Study. Food Chem Toxicol. 2000;38:599-605.  [PubMed]  [DOI]
33.  Tsubono Y, Nishino Y, Komatsu S, Hsieh CC, Kanemura S, Tsuji I, Nakatsuka H, Fukao A, Satoh H, Hisamichi S. Green tea and the risk of gastric cancer in Japan. N Engl J Med. 2001;344:632-636.  [PubMed]  [DOI]
34.  McCullough ML, Robertson AS, Jacobs EJ, Chao A, Calle EE, Thun MJ. A prospective study of diet and stomach cancer mortality in United States men and women. Cancer Epidemiol Biomarkers Prev. 2001;10:1201-1205.  [PubMed]  [DOI]
35.  Nagata C, Takatsuka N, Kawakami N, Shimizu H. A prospective cohort study of soy product intake and stomach cancer death. Br J Cancer. 2002;87:31-36.  [PubMed]  [DOI]
36.  Ngoan LT, Mizoue T, Fujino Y, Tokui N, Yoshimura T. Dietary factors and stomach cancer mortality. Br J Cancer. 2002;87:37-42.  [PubMed]  [DOI]
37.  Kobayashi M, Tsubono Y, Sasazuki S, Sasaki S, Tsugane S. Vegetables, fruit and risk of gastric cancer in Japan: a 10-year follow-up of the JPHC Study Cohort I. Int J Cancer. 2002;102:39-44.  [PubMed]  [DOI]
38.  Masaki M, Sugimori H, Nakamura K, Tadera M. Dietary patterns and stomach cancer among middle-aged male workers in Tokyo. Asian Pac J Cancer Prev. 2003;4:61-66.  [PubMed]  [DOI]
39.  Khan MM, Goto R, Kobayashi K, Suzumura S, Nagata Y, Sonoda T, Sakauchi F, Washio M, Mori M. Dietary habits and cancer mortality among middle aged and older Japanese living in hokkaido, Japan by cancer site and sex. Asian Pac J Cancer Prev. 2004;5:58-65.  [PubMed]  [DOI]
40.  Kim MK, Sasaki S, Sasazuki S, Tsugane S. Prospective study of three major dietary patterns and risk of gastric cancer in Japan. Int J Cancer. 2004;110:435-442.  [PubMed]  [DOI]
41.  Sasazuki S, Inoue M, Hanaoka T, Yamamoto S, Sobue T, Tsugane S. Green tea consumption and subsequent risk of gastric cancer by subsite: the JPHC Study. Cancer Causes Control. 2004;15:483-491.  [PubMed]  [DOI]
42.  González CA, Jakszyn P, Pera G, Agudo A, Bingham S, Palli D, Ferrari P, Boeing H, del Giudice G, Plebani M. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98:345-354.  [PubMed]  [DOI]
43.  Jakszyn P, Bingham S, Pera G, Agudo A, Luben R, Welch A, Boeing H, Del Giudice G, Palli D, Saieva C. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis. 2006;27:1497-1501.  [PubMed]  [DOI]
44.  González CA, Pera G, Agudo A, Bueno-de-Mesquita HB, Ceroti M, Boeing H, Schulz M, Del Giudice G, Plebani M, Carneiro F. Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Cancer. 2006;118:2559-2566.  [PubMed]  [DOI]
45.  You WC, Blot WJ, Chang YS, Ershow A, Yang ZT, An Q, Henderson BE, Fraumeni JF, Wang TG. Allium vegetables and reduced risk of stomach cancer. J Natl Cancer Inst. 1989;81:162-164.  [PubMed]  [DOI]
46.  Hansson LE, Nyrén O, Bergström R, Wolk A, Lindgren A, Baron J, Adami HO. Diet and risk of gastric cancer. A population-based case-control study in Sweden. Int J Cancer. 1993;55:181-189.  [PubMed]  [DOI]
47.  Gao CM, Takezaki T, Ding JH, Li MS, Tajima K. Protective effect of allium vegetables against both esophageal and stomach cancer: a simultaneous case-referent study of a high-epidemic area in Jiangsu Province, China. Jpn J Cancer Res. 1999;90:614-621.  [PubMed]  [DOI]
48.  Takezaki T, Gao CM, Wu JZ, Ding JH, Liu YT, Zhang Y, Li SP, Su P, Liu TK, Tajima K. Dietary protective and risk factors for esophageal and stomach cancers in a low-epidemic area for stomach cancer in Jiangsu Province, China: comparison with those in a high-epidemic area. Jpn J Cancer Res. 2001;92:1157-1165.  [PubMed]  [DOI]
49.  Setiawan VW, Yu GP, Lu QY, Lu ML, Yu SZ, Mu L, Zhang JG, Kurtz RC, Cai L, Hsieh CC. Allium vegetables and stomach cancer risk in China. Asian Pac J Cancer Prev. 2005;6:387-395.  [PubMed]  [DOI]
50.  Setiawan VW, Zhang ZF, Yu GP, Lu QY, Li YL, Lu ML, Wang MR, Guo CH, Yu SZ, Kurtz RC. Protective effect of green tea on the risks of chronic gastritis and stomach cancer. Int J Cancer. 2001;92:600-604.  [PubMed]  [DOI]
51.  Heber D. Vegetables, fruits and phytoestrogens in the prevention of diseases. J Postgrad Med. 2004;50:145-149.  [PubMed]  [DOI]
52.  Kazi A, Smith DM, Daniel K, Zhong S, Gupta P, Bosley ME, Dou QP. Potential molecular targets of tea polyphenols in human tumor cells: significance in cancer prevention. In Vivo. 2002;16:397-403.  [PubMed]  [DOI]
53.  Kono S, Ikeda M, Tokudome S, Kuratsune M. A case-control study of gastric cancer and diet in northern Kyushu, Japan. Jpn J Cancer Res. 1988;79:1067-1074.  [PubMed]  [DOI]
54.  Yu GP, Hsieh CC, Wang LY, Yu SZ, Li XL, Jin TH. Green-tea consumption and risk of stomach cancer: a population-based case-control study in Shanghai, China. Cancer Causes Control. 1995;6:532-538.  [PubMed]  [DOI]
55.  Ji BT, Chow WH, Yang G, McLaughlin JK, Gao RN, Zheng W, Shu XO, Jin F, Fraumeni JF, Gao YT. The influence of cigarette smoking, alcohol, and green tea consumption on the risk of carcinoma of the cardia and distal stomach in Shanghai, China. Cancer. 1996;77:2449-2457.  [PubMed]  [DOI]
56.  Gao CM, Takezaki T, Wu JZ, Li ZY, Liu YT, Li SP, Ding JH, Su P, Hu X, Xu TL. Glutathione-S-transferases M1 (GSTM1) and GSTT1 genotype, smoking, consumption of alcohol and tea and risk of esophageal and stomach cancers: a case-control study of a high-incidence area in Jiangsu Province, China. Cancer Lett. 2002;188:95-102.  [PubMed]  [DOI]
57.  Ye WM, Yi YN, Luo RX, Zhou TS, Lin RT, Chen GD. Diet and gastric cancer: a casecontrol study in Fujian Province, China. World J Gastroenterol. 1998;4:516-518.  [PubMed]  [DOI]
58.  Rao DN, Ganesh B, Dinshaw KA, Mohandas KM. A case-control study of stomach cancer in Mumbai, India. Int J Cancer. 2002;99:727-731.  [PubMed]  [DOI]
59.  Trichopoulos D, Ouranos G, Day NE, Tzonou A, Manousos O, Papadimitriou C, Trichopoulos A. Diet and cancer of the stomach: a case-control study in Greece. Int J Cancer. 1985;36:291-297.  [PubMed]  [DOI]
60.  Agudo A, González CA, Marcos G, Sanz M, Saigi E, Verge J, Boleda M, Ortego J. Consumption of alcohol, coffee, and tobacco, and gastric cancer in Spain. Cancer Causes Control. 1992;3:137-143.  [PubMed]  [DOI]
61.  Chow WH, Swanson CA, Lissowska J, Groves FD, Sobin LH, Nasierowska-Guttmejer A, Radziszewski J, Regula J, Hsing AW, Jagannatha S. Risk of stomach cancer in relation to consumption of cigarettes, alcohol, tea and coffee in Warsaw, Poland. Int J Cancer. 1999;81:871-876.  [PubMed]  [DOI]
62.  Lee HH, Wu HY, Chuang YC, Chang AS, Chao HH, Chen KY, Chen HK, Lai GM, Huang HH, Chen CJ. Epidemiologic characteristics and multiple risk factors of stomach cancer in Taiwan. Anticancer Res. 1990;10:875-881.  [PubMed]  [DOI]
63.  Hoshiyama Y, Kawaguchi T, Miura Y, Mizoue T, Tokui N, Yatsuya H, Sakata K, Kondo T, Kikuchi S, Toyoshima H. A nested case-control study of stomach cancer in relation to green tea consumption in Japan. Br J Cancer. 2004;90:135-138.  [PubMed]  [DOI]
64.  Hoshiyama Y, Kawaguchi T, Miura Y, Mizoue T, Tokui N, Yatsuya H, Sakata K, Kondo T, Kikuchi S, Toyoshima H. A prospective study of stomach cancer death in relation to green tea consumption in Japan. Br J Cancer. 2002;87:309-313.  [PubMed]  [DOI]
65.  Yu GP, Hsieh CC. Risk factors for stomach cancer: a population-based case-control study in Shanghai. Cancer Causes Control. 1991;2:169-174.  [PubMed]  [DOI]
66.  Sun CL, Yuan JM, Lee MJ, Yang CS, Gao YT, Ross RK, Yu MC. Urinary tea polyphenols in relation to gastric and esophageal cancers: a prospective study of men in Shanghai, China. Carcinogenesis. 2002;23:1497-1503.  [PubMed]  [DOI]
67.  Wang GQ, Dawsey SM, Li JY, Taylor PR, Li B, Blot WJ, Weinstein WM, Liu FS, Lewin KJ, Wang H. Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the General Population Trial in Linxian, China. Cancer Epidemiol Biomarkers Prev. 1994;3:161-166.  [PubMed]  [DOI]
68.  Varis K, Taylor PR, Sipponen P, Samloff IM, Heinonen OP, Albanes D, Härkönen M, Huttunen JK, Laxén F, Virtamo J. Gastric cancer and premalignant lesions in atrophic gastritis: a controlled trial on the effect of supplementation with alpha-tocopherol and beta-carotene. The Helsinki Gastritis Study Group. Scand J Gastroenterol. 1998;33:294-300.  [PubMed]  [DOI]
69.  Malila N, Taylor PR, Virtanen MJ, Korhonen P, Huttunen JK, Albanes D, Virtamo J. Effects of alpha-tocopherol and beta-carotene supplementation on gastric cancer incidence in male smokers (ATBC Study, Finland). Cancer Causes Control. 2002;13:617-623.  [PubMed]  [DOI]
70.  Zhu S, Mason J, Shi Y, Hu Y, Li R, Wahg M, Zhou Y, Jin G, Xie Y, Wu G. The effect of folic acid on the development of stomach and other gastrointestinal cancers. Chin Med J (Engl). 2003;116:15-19.  [PubMed]  [DOI]
71.  Li H, Li HQ, Wang Y, Xu HX, Fan WT, Wang ML, Sun PH, Xie XY. An intervention study to prevent gastric cancer by micro-selenium and large dose of allitridum. Chin Med J (Engl). 2004;117:1155-1160.  [PubMed]  [DOI]
72.  An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet. 1993;341:1359-1362.  [PubMed]  [DOI]
73.  Schistosomes , liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241.  [PubMed]  [DOI]
74.  Loffeld RJ, Willems I, Flendrig JA, Arends JW. Helicobacter pylori and gastric carcinoma. Histopathology. 1990;17:537-541.  [PubMed]  [DOI]
75.  Caruso ML, Fucci L. Histological identification of Helicobacter pylori in early and advanced gastric cancer. J Clin Gastroenterol. 1990;12:601-602.  [PubMed]  [DOI]
76.  Talley NJ, Zinsmeister AR, Weaver A, DiMagno EP, Carpenter HA, Perez-Perez GI, Blaser MJ. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst. 1991;83:1734-1739.  [PubMed]  [DOI]
77.  Sipponen P, Kosunen TU, Valle J, Riihelä M, Seppälä K. Helicobacter pylori infection and chronic gastritis in gastric cancer. J Clin Pathol. 1992;45:319-323.  [PubMed]  [DOI]
78.  Kuipers EJ, Gracia-Casanova M, Peña AS, Pals G, Van Kamp G, Kok A, Kurz-Pohlmann E, Pels NF, Meuwissen SG. Helicobacter pylori serology in patients with gastric carcinoma. Scand J Gastroenterol. 1993;28:433-437.  [PubMed]  [DOI]
79.  Estevens J, Fidalgo P, Tendeiro T, Chagas C, Ferra A, Leitao CN, Mira FC. Anti-Helicobacter pylori antibodies prevalence and gastric adenocarcinoma in Portugal: report of a case-control study. Eur J Cancer Prev. 1993;2:377-380.  [PubMed]  [DOI]
80.  Blaser MJ, Kobayashi K, Cover TL, Cao P, Feurer ID, Pérez-Pérez GI. Helicobacter pylori infection in Japanese patients with adenocarcinoma of the stomach. Int J Cancer. 1993;55:799-802.  [PubMed]  [DOI]
81.  Tatsuta M, Iishi H, Okuda S, Taniguchi H, Yokota Y. The association of Helicobacter pylori with differentiated-type early gastric cancer. Cancer. 1993;72:1841-1845.  [PubMed]  [DOI]
82.  Buruk F, Berberoglu U, Pak I, Aksaz E, Celen O. Gastric cancer and Helicobacter pylori infection. Br J Surg. 1993;80:378-379.  [PubMed]  [DOI]
83.  Hansson LE, Engstrand L, Nyrén O, Evans DJ, Lindgren A, Bergström R, Andersson B, Athlin L, Bendtsen O, Tracz P. Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. Gastroenterology. 1993;105:1098-1103.  [PubMed]  [DOI]
84.  Archimandritis A, Bitsikas J, Tjivras M, Anastasakou E, Tsavaris N, Kalogeras D, Davaris P, Fertakis A. Non-cardia gastric adenocarcinoma and Helicobacter pylori infection. Ital J Gastroenterol. 1993;25:368-371.  [PubMed]  [DOI]
85.  Lin JT, Wang JT, Wang TH, Wu MS, Chen CJ. Helicobacter pylori infection in early and advanced gastric adenocarcinoma: a seroprevalence study in 143 Taiwanese patients. Hepatogastroenterology. 1993;40:596-599.  [PubMed]  [DOI]
86.  Hu PJ, Mitchell HM, Li YY, Zhou MH, Hazell SL. Association of Helicobacter pylori with gastric cancer and observations on the detection of this bacterium in gastric cancer cases. Am J Gastroenterol. 1994;89:1806-1810.  [PubMed]  [DOI]
87.  Sipponen P, Riihelä M, Hyvärinen H, Seppälä K. Chronic nonatropic ('superficial') gastritis increases the risk of gastric carcinoma. A case-control study. Scand J Gastroenterol. 1994;29:336-340.  [PubMed]  [DOI]
88.  Asaka M, Kimura T, Kato M, Kudo M, Miki K, Ogoshi K, Kato T, Tatsuta M, Graham DY. Possible role of Helicobacter pylori infection in early gastric cancer development. Cancer. 1994;73:2691-2694.  [PubMed]  [DOI]
89.  Kikuchi S, Wada O, Nakajima T, Nishi T, Kobayashi O, Konishi T, Inaba Y. Serum anti-Helicobacter pylori antibody and gastric carcinoma among young adults. Research Group on Prevention of Gastric Carcinoma among Young Adults. Cancer. 1995;75:2789-2793.  [PubMed]  [DOI]
90.  Rudi J, Müller M, von Herbay A, Zuna I, Raedsch R, Stremmel W, Räth U. Lack of association of Helicobacter pylori seroprevalence and gastric cancer in a population with low gastric cancer incidence. Scand J Gastroenterol. 1995;30:958-963.  [PubMed]  [DOI]
91.  Fukuda H, Saito D, Hayashi S, Hisai H, Ono H, Yoshida S, Oguro Y, Noda T, Sato T, Katoh M. Helicobacter pylori infection, serum pepsinogen level and gastric cancer: a case-control study in Japan. Jpn J Cancer Res. 1995;86:64-71.  [PubMed]  [DOI]
92.  Menegatti M, Vaira D, Miglioli M, Holton J, Vergura MR, Biasco G, Petronelli A, Ricci C, Azzarone P, Gusmaroli R. Helicobacter pylori in patients with gastric and nongastric cancer. Am J Gastroenterol. 1995;90:1278-1281.  [PubMed]  [DOI]
93.  Asaka M, Kato M, Kudo M, Katagiri M, Nishikawa K, Yoshida J, Takeda H, Miki K. Relationship between Helicobacter pylori infection, atrophic gastritis and gastric carcinoma in a Japanese population. Eur J Gastroenterol Hepatol. 1995;7 Suppl 1:S7-10.  [PubMed]  [DOI]
94.  Hatz RA, Lehn N, Leyh S, Kaps MF, Bayerdörffer E, Stolte M, Schildberg FW. [Prevalence of Helicobacter pylori infection in stomach carcinoma]. Chirurg. 1996;67:403-408.  [PubMed]  [DOI]
95.  Shibata T, Imoto I, Ohuchi Y, Taguchi Y, Takaji S, Ikemura N, Nakao K, Shima T. Helicobacter pylori infection in patients with gastric carcinoma in biopsy and surgical resection specimens. Cancer. 1996;77:1044-1049.  [PubMed]  [DOI]
96.  Kato S, Onda M, Matsukura N, Tokunaga A, Matsuda N, Yamashita K, Shields PG. Genetic polymorphisms of the cancer related gene and Helicobacter pylori infection in Japanese gastric cancer patients. An age and gender matched case-control study. Cancer. 1996;77:1654-1661.  [PubMed]  [DOI]
97.  Kokkola A, Valle J, Haapiainen R, Sipponen P, Kivilaakso E, Puolakkainen P. Helicobacter pylori infection in young patients with gastric carcinoma. Scand J Gastroenterol. 1996;31:643-647.  [PubMed]  [DOI]
98.  Menegatti M, Vaira D, Holton J, Miranda F, Ricci C, Gusmaroli R, Ainley C, Miglioli M, Barbara L. Serological response to Helicobacter pylori in gastric and non-gastric cancer. Clin Sci (Lond). 1996;91:219-223.  [PubMed]  [DOI]
99.  Sivaprakash R, Rao UA, Thyagarajan SP, Ramathilakam B, Jayanthi V. Investigation for the prevalence of Helicobacter pylori infection in patients with gastric carcinoma in Madras, India. Jpn J Med Sci Biol. 1996;49:49-56.  [PubMed]  [DOI]
100.  Kim HY, Cho BD, Chang WK, Kim DJ, Kim YB, Park CK, Shin HS, Yoo JY. Helicobacter pylori infection and the risk of gastric cancer among the Korean population. J Gastroenterol Hepatol. 1997;12:100-103.  [PubMed]  [DOI]
101.  Miehlke S, Hackelsberger A, Meining A, von Arnim U, Müller P, Ochsenkühn T, Lehn N, Malfertheiner P, Stolte M, Bayerdörffer E. Histological diagnosis of Helicobacter pylori gastritis is predictive of a high risk of gastric carcinoma. Int J Cancer. 1997;73:837-839.  [PubMed]  [DOI]
102.  Shi Y, Li J, Li M, Wang L, Guo W, Qin D, Geng C, Forman D, Newell DG, Peto R. Association of Helicobacter pylori infection with precancerous lesions and stomach cancer: a case-control study in Yangzhong County. Chin Med Sci J. 1997;12:175-180.  [PubMed]  [DOI]
103.  Barreto-Zuñiga R, Maruyama M, Kato Y, Aizu K, Ohta H, Takekoshi T, Bernal SF. Significance of Helicobacter pylori infection as a risk factor in gastric cancer: serological and histological studies. J Gastroenterol. 1997;32:289-294.  [PubMed]  [DOI]
104.  Martín-de-Argila C, Boixeda D, Redondo C, Alvarez I, Gisbert JP, García Plaza A, Cantón R. Relation between histologic subtypes and location of gastric cancer and Helicobacter pylori. Scand J Gastroenterol. 1997;32:303-307.  [PubMed]  [DOI]
105.  Azuma T, Ito S, Sato F, Yamazaki Y, Miyaji H, Ito Y, Suto H, Kuriyama M, Kato T, Kohli Y. The role of the HLA-DQA1 gene in resistance to atrophic gastritis and gastric adenocarcinoma induced by Helicobacter pylori infection. Cancer. 1998;82:1013-1018.  [PubMed]  [DOI]
106.  Komoto K, Haruma K, Kamada T, Tanaka S, Yoshihara M, Sumii K, Kajiyama G, Talley NJ. Helicobacter pylori infection and gastric neoplasia: correlations with histological gastritis and tumor histology. Am J Gastroenterol. 1998;93:1271-1276.  [PubMed]  [DOI]
107.  Wu MS, Shun CT, Lee WC, Chen CJ, Wang HP, Lee WJ, Lin JT. Gastric cancer risk in relation to Helicobacter pylori infection and subtypes of intestinal metaplasia. Br J Cancer. 1998;78:125-128.  [PubMed]  [DOI]
108.  Whiting JL, Hallissey MT, Fielding JW, Dunn J. Screening for gastric cancer by Helicobacter pylori serology: a retrospective study. Br J Surg. 1998;85:408-411.  [PubMed]  [DOI]
109.  Lee BM, Jang JJ, Kim JS, You YC, Chun SA, Kim HS, Han HM, Ahn MY, Byun SH. Association of Helicobacter pylori infection with gastric adenocarcinoma. Jpn J Cancer Res. 1998;89:597-603.  [PubMed]  [DOI]
110.  Kikuchi S, Crabtree JE, Forman D, Kurosawa M. Association between infections with CagA-positive or -negative strains of Helicobacter pylori and risk for gastric cancer in young adults. Research Group on Prevention of Gastric Carcinoma Among Young Adults. Am J Gastroenterol. 1999;94:3455-3459.  [PubMed]  [DOI]
111.  Zhang ZF, Kurtz RC, Klimstra DS, Yu GP, Sun M, Harlap S, Marshall JR. Helicobacter pylori infection on the risk of stomach cancer and chronic atrophic gastritis. Cancer Detect Prev. 1999;23:357-367.  [PubMed]  [DOI]
112.  Cai L, Yu SZ, Zhang ZF. Helicobacter pylori infection and risk of gastric cancer in Changle County,Fujian Province,China. World J Gastroenterol. 2000;6:374-376.  [PubMed]  [DOI]
113.  Enroth H, Kraaz W, Engstrand L, Nyrén O, Rohan T. Helicobacter pylori strain types and risk of gastric cancer: a case-control study. Cancer Epidemiol Biomarkers Prev. 2000;9:981-985.  [PubMed]  [DOI]
114.  Chang WK, Kim HY, Kim DJ, Lee J, Park CK, Yoo JY, Kim HJ, Kim MK, Choi BY, Choi HS. Association between Helicobacter pylori infection and the risk of gastric cancer in the Korean population: prospective case-controlled study. J Gastroenterol. 2001;36:816-822.  [PubMed]  [DOI]
115.  Ekström AM, Held M, Hansson LE, Engstrand L, Nyrén O. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology. 2001;121:784-791.  [PubMed]  [DOI]
116.  Fujioka N, Fahey MT, Hamada GS, Nishimoto IN, Kowalski LP, Iriya K, Rodrigues JJ, Tajiri H, Tsugane S. Serological Immunoglobulin G antibody titers to Helicobacter pylori in Japanese Brazilian and Non-Japanese Brazilian gastric cancer patients and controls in São Paulo. Jpn J Cancer Res. 2001;92:829-835.  [PubMed]  [DOI]
117.  Konturek SJ, Starzynska T, Konturek PC, Karczewska E, Marlicz K, Lawniczak M, Jaroszewicz-Heigelman H, Bielanski W, Hartwich A, Ziemniak A. Helicobacter pylori and CagA status, serum gastrin, interleukin-8 and gastric acid secretion in gastric cancer. Scand J Gastroenterol. 2002;37:891-898.  [PubMed]  [DOI]
118.  Sriamporn S, Setiawan V, Pisani P, Suwanrungruang K, Sirijaichingkul S, Mairiang P, Parkin DM. Gastric Cancer: the Roles of Diet, Alcohol Drinking, Smoking and Helicobacter pylori in Northeastern Thailand. Asian Pac J Cancer Prev. 2002;3:345-352.  [PubMed]  [DOI]
119.  Wu AH, Crabtree JE, Bernstein L, Hawtin P, Cockburn M, Tseng CC, Forman D. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer. 2003;103:815-821.  [PubMed]  [DOI]
120.  Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol. 2004;159:252-258.  [PubMed]  [DOI]
121.  Machida-Montani A, Sasazuki S, Inoue M, Natsukawa S, Shaura K, Koizumi Y, Kasuga Y, Hanaoka T, Tsugane S. Association of Helicobacter pylori infection and environmental factors in non-cardia gastric cancer in Japan. Gastric Cancer. 2004;7:46-53.  [PubMed]  [DOI]
122.  Kato M, Asaka M, Shimizu Y, Nobuta A, Takeda H, Sugiyama T. Relationship between Helicobacter pylori infection and the prevalence, site and histological type of gastric cancer. Aliment Pharmacol Ther. 2004;20 Suppl 1:85-89.  [PubMed]  [DOI]
123.  Nomura AM, Kolonel LN, Miki K, Stemmermann GN, Wilkens LR, Goodman MT, Perez-Perez GI, Blaser MJ. Helicobacter pylori, pepsinogen, and gastric adenocarcinoma in Hawaii. J Infect Dis. 2005;191:2075-2081.  [PubMed]  [DOI]
124.  Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325:1132-1136.  [PubMed]  [DOI]
125.  Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127-1131.  [PubMed]  [DOI]
126.  Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, Sitas F. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991;302:1302-1305.  [PubMed]  [DOI]
127.  Parsonnet J, Samloff IM, Nelson LM, Orentreich N, Vogelman JH, Friedman GD. Helicobacter pylori, pepsinogen, and risk for gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 1993;2:461-466.  [PubMed]  [DOI]
128.  Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, Stemmermann GN, Nomura A. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 1995;55:2111-2115.  [PubMed]  [DOI]
129.  Lin JT, Wang LY, Wang JT, Wang TH, Yang CS, Chen CJ. A nested case-control study on the association between Helicobacter pylori infection and gastric cancer risk in a cohort of 9775 men in Taiwan. Anticancer Res. 1995;15:603-606.  [PubMed]  [DOI]
130.  Aromaa A, Kosunen TU, Knekt P, Maatela J, Teppo L, Heinonen OP, Härkönen M, Hakama MK. Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer. Am J Epidemiol. 1996;144:142-149.  [PubMed]  [DOI]
131.  Webb PM, Yu MC, Forman D, Henderson BE, Newell DG, Yuan JM, Gao YT, Ross RK. An apparent lack of association between Helicobacter pylori infection and risk of gastric cancer in China. Int J Cancer. 1996;67:603-607.  [PubMed]  [DOI]
132.  Simán JH, Forsgren A, Berglund G, Florén CH. Association between Helicobacter pylori and gastric carcinoma in the city of Malmö, Sweden. A prospective study. Scand J Gastroenterol. 1997;32:1215-1221.  [PubMed]  [DOI]
133.  Watanabe Y, Kurata JH, Mizuno S, Mukai M, Inokuchi H, Miki K, Ozasa K, Kawai K. Helicobacter pylori infection and gastric cancer. A nested case-control study in a rural area of Japan. Dig Dis Sci. 1997;42:1383-1387.  [PubMed]  [DOI]
134.  Yuan JM, Yu MC, Xu WW, Cockburn M, Gao YT, Ross RK. Helicobacter pylori infection and risk of gastric cancer in Shanghai, China: updated results based upon a locally developed and validated assay and further follow-up of the cohort. Cancer Epidemiol Biomarkers Prev. 1999;8:621-624.  [PubMed]  [DOI]
135.  Hansen S, Melby KK, Aase S, Jellum E, Vollset SE. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case-control study. Scand J Gastroenterol. 1999;34:353-360.  [PubMed]  [DOI]
136.  You WC, Zhang L, Gail MH, Chang YS, Liu WD, Ma JL, Li JY, Jin ML, Hu YR, Yang CS. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst. 2000;92:1607-1612.  [PubMed]  [DOI]
137.  Tulinius H, Ogmundsdottir HM, Kristinsson KG, Sigvaldason H, Sigvaldadottir E, Kristjansdottir G, Sigfusson N. Helicobacter pylori antibodies and gastric cancer in Iceland - The decline in IgG antibody level is a risk factor. APMIS. 2001;109:835-841.  [PubMed]  [DOI]
138.  Simán JH, Forsgren A, Berglund G, Florén CH. Tobacco smoking increases the risk for gastric adenocarcinoma among Helicobacter pylori-infected individuals. Scand J Gastroenterol. 2001;36:208-213.  [PubMed]  [DOI]
139.  Limburg P, Qiao Y, Mark S, Wang G, Perez-Perez G, Blaser M, Wu Y, Zou X, Dong Z, Taylor P. Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China. J Natl Cancer Inst. 2001;93:226-233.  [PubMed]  [DOI]
140.  Nomura AM, Lee J, Stemmermann GN, Nomura RY, Perez-Perez GI, Blaser MJ. Helicobacter pylori CagA seropositivity and gastric carcinoma risk in a Japanese American population. J Infect Dis. 2002;186:1138-1144.  [PubMed]  [DOI]
141.  Kosunen TU, Seppala K, Sarna S, Aromaa A, Knekt P, Virtamo J, Salomaa-Rasanen A, Rautelin H. Association of Helicobacter pylori IgA antibodies with the risk of peptic ulcer disease and gastric cancer. World J Gastroenterol. 2005;11:6871-6874.  [PubMed]  [DOI]
142.  Shin A, Shin HR, Kang D, Park SK, Kim CS, Yoo KY. A nested case-control study of the association of Helicobacter pylori infection with gastric adenocarcinoma in Korea. Br J Cancer. 2005;92:1273-1275.  [PubMed]  [DOI]
143.  Knekt P, Teppo L, Aromaa A, Rissanen H, Kosunen TU. Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period. Int J Cancer. 2006;119:702-705.  [PubMed]  [DOI]
144.  Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998;114:1169-1179.  [PubMed]  [DOI]
145.  Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts.  Gut. 2001;49:347-353.  [PubMed]  [DOI]
146.  Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784-789.  [PubMed]  [DOI]
147.  Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology. 2003;125:1636-1644.  [PubMed]  [DOI]
148.  Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187-194.  [PubMed]  [DOI]
149.  Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst. 2000;92:1881-1888.  [PubMed]  [DOI]
150.  Yamaguchi N, Kakizoe T. Synergistic interaction between Helicobacter pylori gastritis and diet in gastric cancer. Lancet Oncol. 2001;2:88-94.  [PubMed]  [DOI]
151.  Nardone G, Rocco A, Malfertheiner P. Review article: helicobacter pylori and molecular events in precancerous gastric lesions. Aliment Pharmacol Ther. 2004;20:261-270.  [PubMed]  [DOI]
152.  Davies GR, Simmonds NJ, Stevens TR, Sheaff MT, Banatvala N, Laurenson IF, Blake DR, Rampton DS. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut. 1994;35:179-185.  [PubMed]  [DOI]
153.  Farinati F, Cardin R, Degan P, Rugge M, Mario FD, Bonvicini P, Naccarato R. Oxidative DNA damage accumulation in gastric carcinogenesis. Gut. 1998;42:351-356.  [PubMed]  [DOI]
154.  Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol. 1995;19 Suppl 1:S37-S43.  [PubMed]  [DOI]
155.  Sander J, Burkle G, Schweinberg F. Induction of tumors by nitrite and secondary amines or amides. Topics in chemical carcinogenesis. Baltimore: University Park Press; 1972;292-312.  [PubMed]  [DOI]
156.  Lee SA, Kang D, Shim KN, Choe JW, Hong WS, Choi H. Effect of diet and Helicobacter pylori infection to the risk of early gastric cancer. J Epidemiol. 2003;13:162-168.  [PubMed]  [DOI]
157.  López-Carrillo L, López-Cervantes M, Robles-Díaz G, Ramírez-Espitia A, Mohar-Betancourt A, Meneses-García A, López-Vidal Y, Blair A. Capsaicin consumption, Helicobacter pylori positivity and gastric cancer in Mexico. Int J Cancer. 2003;106:277-282.  [PubMed]  [DOI]
158.  Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand. 1965;64:31-49.  [PubMed]  [DOI]
159.  Kato I, Tominaga S, Ito Y, Kobayashi S, Yoshii Y, Matsuura A, Kameya A, Kano T. A comparative case-control analysis of stomach cancer and atrophic gastritis. Cancer Res. 1990;50:6559-6564.  [PubMed]  [DOI]
160.  Boeing H, Jedrychowski W, Wahrendorf J, Popiela T, Tobiasz-Adamczyk B, Kulig A. Dietary risk factors in intestinal and diffuse types of stomach cancer: a multicenter case-control study in Poland. Cancer Causes Control. 1991;2:227-233.  [PubMed]  [DOI]
161.  Harrison LE, Zhang ZF, Karpeh MS, Sun M, Kurtz RC. The role of dietary factors in the intestinal and diffuse histologic subtypes of gastric adenocarcinoma: a case-control study in the U.S. Cancer. 1997;80:1021-1028.  [PubMed]  [DOI]
162.  Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H, Shiratori Y. The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol. 2005;100:1037-1042.  [PubMed]  [DOI]
163.  Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet. 1996;348:150-154.  [PubMed]  [DOI]
164.  Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167-180.  [PubMed]  [DOI]